Download PDF
Thromb Haemost 1997; 78(01): 726-729
DOI: 10.1055/s-0038-1657619
Disorders of hemostasis in childhood
Schattauer GmbH Stuttgart

Prophylaxis in Children with Hemophilia: Is it the Optimal Treatment?

Jeanne M Lusher
The Children’s Hospital of Michigan, Detroit, Ml, USA
› Author Affiliations
Further Information

Publication History

Publication Date:
12 July 2018 (online)

  PDF Download  Permissions and Reprints
 

  • References

  • 1 Onwuzurike N, Warrier I, Lusher JM. Types of bleeding seen during the first 30 months of life in children with severe haemophilia A and B. Haemophilia 1996; 02: 137-140
    PubMedGoogle Scholar
  • 2 Pettersson H, Ahlberg Å, Nilsson IM. A radiologic classification of hemophilic arthropathy. Clin Orthop 1980; 149: 153-159
    PubMedGoogle Scholar
  • 3 Ahlberg Å. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculoskeletal manifestations of haemophilia A and B. Acta Orthop Scand 1965; 77 (Suppl) 07-80
    PubMedGoogle Scholar
  • 4 Heijnen L, de GrootC, Prevo A. Arthropathy in hemophiliacs. Comparing long term prophylaxis with treatment on demand. pres, at XV Congress. World Federation of Hemophilia: Stockholm, Sweden; 1983 abstract booklet, p. 49
    PubMedGoogle Scholar
  • 5 Brettler DB, Levine PH. Clinical manifestations and therapy of inherited coagulation factor deficiencies. In: Hemostasis and Thrombosis. Basic Principles and Clinical Practice, 3rd ed. Colman RW, Hirsch J, Marder VJ, Salzman EW. eds. J.B. Lippincott Company; Philadelphia, PA: 1994. pp 169-183
    Google Scholar
  • 6 Roberts HR, Hoffman M. Hemophilia and related conditions-inherited deficiencies of prothrombin (factor II), factor V, and factors VII to XII. In: Williams Hematology, 5th ed. Beutler E, Lichtman MA, Coller BS, Kipps TJ. eds. McGraw-Hill; New York, NY: 1995. pp 1413-1439
    Google Scholar
  • 7 Furie B, Limentani SA, Rosenfield CG. A practical guide to the evaluation and treatment of hemophilia. Blood 1994; 84: 03-09
    PubMedGoogle Scholar
  • 8 Rickard KA. Guidelines for therapy and optimal dosages of coagulation factors for treatment of bleeding and surgery in haemophilia. Haemophilia 1995; 01 (Suppl. 01) 08-13
    PubMedGoogle Scholar
  • 9 Association of Hemophilia Clinic Directors of Canada. Hemophilia and von Willebrand’s disease 2. Management. Canadian Med Assocn J 1995; 153: 147-157
    PubMed
  • 10 Nilsson IM, Hedner U, Ahlberg A. Haemophilia prophylaxis in Sweden. Acta Paediatr Scand 1976; 65: 129-135
    CrossrefPubMedGoogle Scholar
  • 11 Nilsson I, Berntorp E, Lӧfqvist T, Pettersson H. Twenty-five years’ experience of prophylactic treatment in severe hemophilia A and B. J Intern Med 1992; 232: 25-32
    CrossrefPubMedGoogle Scholar
  • 12 Petrini P, Lindvall N, Egberg N, Blombäck M. Prophylaxis with factor concentrate in preventing hemophilic arthropathy. Am J Ped Hematol Oncol 1991; 13: 280-287
    CrossrefPubMedGoogle Scholar
  • 13 Ljung RCR, Lindgren A-C, Tengborn L, Petrini P. Issues in prophylaxis for young children in Sweden: the long-term feasibility of venous access. In: Prophylactic treatment of hemophilia A and B: current and future perspectives. New York: Sci and Med; 1994. pp 49-51
    Google Scholar
  • 14 Berntorp E. Methods of hemophilia care delivery; regular prophylaxis vs episodic treatment. Haemophilia 1995; 1 (Suppl. 01) 03-07
    PubMedGoogle Scholar
  • 15 Carlsson M, Berntorp E, Bjӧrkman S, Lindvall K. Pharmacokinetic dosing in prophylactic treatment of hemophilia A. Eur J Haematol 1993; 31: 247-252
    PubMedGoogle Scholar
  • 16 Pettersson H, Gilbert M. Diagnostic Imaging in Hemophilia; Musculoskeletal and other hemorrhagic complications. Springer Verlag; Berlin: 1985. pp 56-65
    Google Scholar
  • 17 Aronstam A, Arblaster PG, Rainsford SG, Turk P. Prophylaxis in haemophilia: a double-blind controlled trial. Br J Haematol 1976; 33: 81-90
    CrossrefPubMedGoogle Scholar
  • 18 Schimpf K, Fischer B, Rothmann P. Die ambulante dauerbehandlung der hämophilie A. Dtsch Med Wochenshr 1976; 101: 141-148
    PubMedGoogle Scholar
  • 19 Morfini M, Mannucci PM, Mariani G. et al Evolution of prophylactic replacement therapy in haemophilia B. Scand J Haematol 1976; 16: 41-47
    PubMedGoogle Scholar
  • 20 van denBergHM, Nieuwenhuis HK, Mauser-Bunschoten EP, Roosendaal G. Hemophilia prophylaxis in the Netherlands. Semin Hematol 1994; 31 (Suppl. 02) 13-15
    PubMedGoogle Scholar
  • 21 Aledort LM, Haschmeyer RH. Pettersson H and the Orthopaedic Outcome Study Group. A longitudinal study of orthopedic outcomes for severe factor VIII deficient hemophiliacs. J Intern Med 1994; 236: 391-399
    CrossrefPubMedGoogle Scholar
  • 22 The National Hemophilia Foundation. Medical and Scientific Advisory Council recommendations concerning prophylaxis. The National Hemophilia Foundation (110 Greene St., N.Y., N.Y., 10012), Medical Bulletin No. 193, Chapter Advisory No. 197 March 11 1994
    PubMedGoogle Scholar
  • 23 Nilsson IM, Berntorp E, Ljung R, Lӧfqvist T, Pettersson H. Prophylactic treatment of severe hemophilia A and B can prevent joint disability. Semin Hematol 1994; 31 (Suppl. 02) 05-09
    PubMedGoogle Scholar
  • 24 Schwaab R, Brackmann H-H, Meyer C, Seehafer J, Kirchgesser M, Haac A, Olek K, Tuddenham EGD, Oldenburg J, Haemophilia A. mutation type determines risk of inhibitor formation. Thrombos Haemostas 1995; 74: 1402-1406
    PubMedGoogle Scholar
  • 25 Aledort LM. Prophylaxis: the next hemophilia treatment (Editorial). J Intern Med 1992; 232: 01-02
    CrossrefPubMedGoogle Scholar
  • 26 Aledort LM, Bohn RL. Prophylaxis and continuous infusion for hemophilia: can we afford it? Blood Coag Fibrinolysis. 1996; 07 (Suppl. 01) S35-S37
    PubMedGoogle Scholar
  • 27 Bohn RL, Avom J. Reimbursement for hemophilia in the United States: current policies and future considerations. Semin Hematol 1994; 31 (Suppl. 02) 26-28
    PubMedGoogle Scholar
  • 28 Steinglass P. Psychosocial issues related to prophylactic therapy for hemophilia. Semin Hematol 1994; 31 (Suppl. 02) 19-25
    PubMedGoogle Scholar
  • 29 Vora AJ, Lilleyman JS. Vascular access in young hemophiliacs: use of indwelling central venous catheters. Internat J Pediatr Hematol Oncol 1994; 01: 521-527
    PubMedGoogle Scholar
  • 30 Warrier I, Baird-Cox K, Cygan ML, Lusher JM. Experience with central venous catheters in children with hemophilia. Thrombos Haemostas 1993; 69: 854 (abstract)
    PubMedGoogle Scholar
  • 31 Reed CR, Sessler CN, Glauser RL, Phelan BA. Central venous catheter infections: concepts and controversies. Intensive Care Med 1995; 21: 177-183
    CrossrefPubMedGoogle Scholar
  • 32 Ljung R, Petrini P, Lindgren A-K, Berntorp E. Implantable central venous catheter facilitates prophylactic treatment in children with haemophilia. Acta Paediatr 1992; 81: 918-920
    CrossrefPubMedGoogle Scholar
  • 33 Raad II, and Bodey GP. Infectious complications of indwelling vascular catheters. Clin Infect Dis 1992; 15: 197-210
    CrossrefPubMedGoogle Scholar
  • 34 Liesner RJ, Khair K, Hann IM. The impact of prophylactic treatment on children with severe haemophilia. Br J Haematol 1996; 92: 973-978
    CrossrefPubMedGoogle Scholar
  • 35 Ljung RCR, Lindgren A-C, Tengborn L, Petrini P. The feasibility of long-term venous access in children with hemophilia. Semin Hematol 1994; 31 (Suppl. 02) 16-18
    PubMedGoogle Scholar
  • 36 Manco-Johnson MJ, Nuss R, Geraghty S, Funk S. A prophylactic program in the United States: experience and issues. Semin Hematol 1994; 31 (Suppl. 02) 10-12
    PubMedGoogle Scholar
  • 37 Nuss R, Kilcoyne R, Geraghty S, Wiedel J, Manco-Johnson M. Utility of magnetic resonance imaging for management of hemophilic arthropathy in children. J Pediatr 1993; 123: 388-392
    CrossrefPubMedGoogle Scholar